Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages

Journal of Immunology

Volumn 182, Issue 5, 2009, Pages 3105-3111

  Eriksson, Fredrik ^a   Tsagozis, Panagiotis ^a   Lundberg, Kajsa ^a   Parsa, Roham ^b   Mangsbo, Sara M ^c   Persson, Mats A A ^b   Harris, Robert A ^b   Pisa, Pavel ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYTOKINE; MYD88 PROTEIN, MOUSE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIOPHAGE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; INNATE IMMUNITY; MELANOMA; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; ANIMAL; APOPTOSIS; BACTERIOPHAGE M13; C57BL MOUSE; CELL CULTURE; COCULTURE; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY;

ANIMALS; APOPTOSIS; BACTERIOPHAGE M13; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; MACROPHAGE ACTIVATION; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; TOLL-LIKE RECEPTORS;

EID: 64849106667     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0800224     Document Type: Article

References (40)

1. Weber, M. S., T. Prod'homme, S. Youssef, S. E. Dunn, C. D. Rundle, L. Lee, J. C. Patarroyo, O. Stuve, R. A. Sobel, L. Steinman, and S. S. Zamvil. 2007. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 13: 935-943.
2. Wang, Y., Y. P. Wang, G. Zheng, V. W. Lee, L. Ouyang, D. H. Chang, D. Mahajan, J. Coombs, Y. M. Wang, S. I. Alexander, and D. C. Harris. 2007. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int. 72: 290-299.
3. Algarra, I., A. Garcia-Lora, T. Cabrera, F. Ruiz-Cabello, and F. Garrido. 2004. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother. 53: 904-910.
4. Delp, K., F. Momburg, C. Hilmes, C. Huber, and B. Seliger. 2000. Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin. Bone Marrow Transplant. 25 Suppl. 2: S88-S95.
5. Restifo, N. P., F. Esquivel, Y. Kawakami, J. W. Yewdell, J. J. Mule, S. A. Rosenberg, and J. R. Bennink. 1993. Identification of human cancers de-ficient in antigen processing. J. Exp. Med. 177: 265-272.
6. Restifo, N. P., F. M. Marincola, Y. Kawakami, J. Taubenberger, J. R. Yannelli, and S. A. Rosenberg. 1996. Loss of functional β 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 88: 100-108.
7. Igney, F. H., C. K. Behrens, and P. H. Krammer. 2005. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo. Int. J. Cancer 113:78-87.
8. Medema, J. P., J. de Jong, L. T. Peltenburg, E. M. Verdegaal, A. Gorter, S. A. Bres, K. L. Franken, M. Hahne, J. P. Albar, C. J. Melief, and R. Offringa. 2001. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc. Natl. Acad. Sci. USA 98: 11515-11520.
9. Dong, H. D., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. F. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800.
10. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
11. Murdoch, C., A. Giannoudis, and C. E. Lewis. 2004. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104: 2224-2234.
12. Duyndam, M. C. A., M. C. G. W. Hilhorst, H. M. M. Schluper, H. M. W. Verheul, P. J. van Diest, G. Kraal, H. M. Pinedo, and E. Boven. 2002. Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am. J. Pathol. 160: 537-548.
13. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A. Sica. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23: 549-555.
14. Sica, A., A. Saccani, B. Bottazzi, N. Polentarutti, A. Vecchi, J. Van Damme, and A. Mantovani. 2000. Autocrine production of IL-10 mediates defective IL-12 production and NF-κB activation in tumor-associated macrophages. J. Immunol. 164: 762-767.
15. Lee, J. R., R. R. Dalton, J. L. Messina, M. D. Sharma, D. M. Smith, R. E. Burgess, F. Mazzella, S. J. Antonia, A. L. Mellor, and D. H. Munn. 2003. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab. Invest. 83:1457-1466.
16. Leek, R. D., C. E. Lewis, R. Whitehouse, M. Greenall, J. Clarke, and A. L. Harris. 1996. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56: 4625-4629.
17. Ono, M., H. Torisu, J. Fukushi, A. Nishie, and M. Kuwano. 1999. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother. Pharmacol. 43 Suppl.: S69-S71.
18. Pollard, J. W. 2004. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4: 71-78.
19. Luo, Y., H. Zhou, J. Krueger, C. Kaplan, S. H. Lee, C. Dolman, D. Markowitz, W. Wu, C. Liu, R. A. Reisfeld, and R. Xiang. 2006. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 116: 2132-2141.
20. Guiducci, C., A. P. Vicari, S. Sangaletti, G. Trinchieri, and M. P. Colombo. 2005. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65:3437-3446.
21. Erwig, L. P., D. C. Kluth, G. M. Walsh, and A. J. Rees. 1998. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J. Immunol. 161: 1983-1988.
22. Gratchev, A., J. Kzhyshkowska, K. Kothe, I. Muller-Molinet, S. Kannookadan, J. Utikal, and S. Goerdt. 2006. Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. Immunobiology 211: 473-486.
23. Eriksson, F., W. D. Culp, R. Massey, L. Egevad, D. Garland, M. A. Persson, and P. Pisa. 2007. Tumor specific phage particles promote tumor regression in a mouse melanoma model. Cancer Immunol. Immunother. 56: 677-687.
24. Smith, G. P. 1985. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228: 1315-1317.
25. Smith, G. P. 1991. Surface presentation of protein epitopes using bacteriophage expression systems. Curr. Opin. Biotechnol. 2: 668-673.
26. Barbas, C. F., 3rd, A. S. Kang, R. A. Lerner, and S. J. Benkovic. 1991. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc. Natl. Acad. Sci. USA 88: 7978-7982.
27. Cuesta, A. M., E. Suarez, M. Larsen, K. B. Jensen, L. Sanz, M. Compte, P. Kristensen, and L. Alvarez-Vallina. 2006. Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I. Immunology 117: 502-506.
28. Mori, K., T. Kubo, Y. Kibayashi, T. Ohkuma, and A. Kaji. 1996. Anti-vaccinia virus effect of M13 bacteriophage DNA. Antiviral Res. 31: 79-86.
29. Bloch, H. 1940. Experimental investigation of the relationship between bacteriophage and malignant tumors. Archiv. für die Gesamte Virusforschung 1: 481-496.
30. Dabrowska, K., A. Opolski, J. Wietrzyk, K. Switala-Jelen, J. Godlewska, J. Boratynski, D. Syper, B. Weber-Dabrowska, and A. Gorski. 2004. Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models. Anticancer Res. 24: 3991-3995.
31. Dabrowska, K., A. Opolski, J. Wietrzyk, K. Switala-Jelen, J. Boratynski, A. Nasulewicz, L. Lipinska, A. Chybicka, M. Kujawa, M. Zabel, et al. 2004. Antitumor activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of β3 integrin signaling pathway. Acta Virol. 48: 241-248.
32. Buhtoiarov, I. N., H. D. Lum, G. Berke, P. M. Sondel, and A. L. Rakhmilevich. 2006. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J. Immunol. 176: 309-318.
33. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150.
34. Lebeis, S. L., B. Bommarius, C. A. Parkos, M. A. Sherman, and D. Kalman. 2007. TLR signaling mediated by MyD88 is required for a protective innate immune response by neutrophils to Citrobacter rodentium. J. Immunol. 179: 566-577.
35. Bronte, V., P. Serafini, A. Mazzoni, D. M. Segal, and P. Zanovello. 2003. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 24: 302-306.
36. Friedl, P., and K. Wolf. 2008. Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res. 68: 7247-7249.
37. O'Sullivan, C., and C. E. Lewis. 1994. Tumour-associated leucocytes: friends or foes in breast carcinoma. J. Pathol. 172: 229-235.
38. Clarke, J. H., J. Y. Cha, M. D. Walsh, F. Gamboni-Robertson, A. Banerjee, L. L. Reznikov, C. A. Dinarello, A. H. Harken, and M. D. McCarter. 2005. Melanoma inhibits macrophage activation by suppressing toll-like receptor 4 signaling. J. Am. Coll. Surg. 201: 418-425.
39. Watkins, S. K., N. K. Egilmez, J. Suttles, and R. D. Stout. 2007. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J. Immunol. 178: 1357-1362.
40. Musiani, P., A. Allione, A. Modica, P. L. Lollini, M. Giovarelli, F. Cavallo, F. Belardelli, G. Forni, and A. Modesti. 1996. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-α, IFN-γ, and TNF-α. Lab. Invest. 74: 146-157.